OmniAb (OABI) Cash from Investing Activities (2021 - 2026)
OmniAb's (OABI) quarterly Cash from Investing Activities came in at $8.4 million in Q1 2026, up 1060.82% year-on-year from $726727.6 in Q1 2025, and up 211.18% on a QoQ basis from $2.7 million in Q4 2025.
OmniAb (OABI) Cash from Investing Activities (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Cash from Investing Activities data on file, last reported at $8.4 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 1060.82% year-over-year to $8.4 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 7.55% decrease from a year earlier, with the FY2025 full-year figure at $6.5 million, down 82.93% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $8.4 million, up from $2.7 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for OABI reached as high as $19.9 million in Q1 2024 and fell as low as -$60.2 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$2.3 million across 5 years, with a median of $2.7 million in 2025.
- Across the five-year window, Cash from Investing Activities sank 841.78% in 2023 and jumped 1060.82% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$60.2 million in 2022, then soared by 107.86% to $4.7 million in 2023, then plunged by 91.86% to $385000.0 in 2024, then soared by 604.16% to $2.7 million in 2025, then soared by 211.18% to $8.4 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $8.4 million in Q1 2026, $2.7 million in Q4 2025, and -$7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | OmniAb | 260.98 Mn | 211.91 Mn | 14.41 Mn | 8.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.44 Mn |
| Mar 31, 2026 | 8.44 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | -7.67 Mn |
| Sep 30, 2025 | -7.67 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Mar 31, 2025 | -878,000.00 |
| Mar 31, 2025 | -878,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Sep 30, 2024 | 4.45 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | 13.11 Mn |
| Jun 30, 2024 | 13.11 Mn |
| Mar 31, 2024 | 19.94 Mn |
| Mar 31, 2024 | 19.94 Mn |
| Dec 31, 2023 | 4.73 Mn |
| Dec 31, 2023 | 4.73 Mn |